Abstract
Swine respiratory disease (SRD) is a complex interaction whereby viral infection predisposes the host to secondary bacterial pulmonary invasion, which may be fatal. Antimicrobial agents remain an important therapy and serve to reduce morbidity and mortality in treated animals. Pradofloxacin is the newest of the veterinary antibiotics to be approved to treat SRD. It is a dual-targeting fluoroquinolone with in vitro and clinical activity against Gram-negative and -positive bacteria, along with atypical agents including anaerobes. In this study, we compared the killing of Actinobacillus pleuropneumoniae, Pasteurella multocida, and Streptococcus suis by pradofloxacin and comparator antibiotics in a 3 h kill assay, using four clinically relevant drug concentrations. Pradofloxacin was bactericidal against the three pathogens, with kill rates ranging from 94.4 to 99.9% (A. pleuropneumoniae) following 15-20 min of exposure to the maximum serum and maximum tissue drug concentration. For P. multocida, the kill rates were 68.7-96.9% following 5-30 min of drug exposure at the maximum serum drug concentration, and 91.7% following 5 min of drug exposure at the maximum tissue drug concentration. For S. suis, pradofloxacin killed 92.4-99.4% and 71.6-97.1% of cells following 60-180 min of drug exposure at the maximum serum and maximum tissue drug concentration, respectively. Pradofloxacin appears to be an important addition to the drugs currently available for treating SRD.